Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Surgical Treatment of Anastomotic Recurrence after Gastrectomy for Gastric Cancer

  • Jung, Jae Jun (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cho, Jong Ho (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Shin, Sumin (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Shim, Young Mog (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2013.08.29
  • Accepted : 2013.11.21
  • Published : 2014.06.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The purpose of this study was to evaluate the outcome of reoperation with curative intent for the treatment of anastomotic recurrent gastric cancer. Methods: Ten patients with anastomotic recurrence of gastric cancer who underwent reoperation from November 1995 to February 2011 were analyzed retrospectively. The time interval between the first operation and reoperation, recurrence pattern, type of surgery, survival, and postoperative outcome were analyzed. Results: The average time to recurrence after initial surgery was 48.8 months (median, 23.5 months). Of the ten patients, eight (80.0%) had recurrence at the esophagojejunostomy, one (10.0 %) at the esophagogastrostomy, and two (20.0%) at the esophagus. Among these patients, five had combined metastasis or invasion to major organs in addition to anastomotic recurrence. Complete resection was achieved in five patients (50.0%), and incomplete resection or bypass surgery was performed in the remaining five patients (50.0%). The overall median survival time was 7.0 months (range, 2.2 to 105.5 months). The median survival time following complete resection and palliative surgery (incomplete resection or bypass surgery) was 28.1 months (range, 4.2 to 105.5 months) and 5.5 months (range, 2.2 to 7.5 months), respectively. Conclusion: Surgical resection of anastomotic recurrent gastric cancer should be implemented only in selected patients in whom complete resection is possible.

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992;216:269-78. https://doi.org/10.1097/00000658-199209000-00006
  3. Inokuchi K. Prolonged survival of stomach cancer patients after extensive surgery and adjuvant treatment: an overview of the Japanese experience. Semin Surg Oncol 1991;7:333-8. https://doi.org/10.1002/ssu.2980070603
  4. Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;27:153-8.
  5. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984;2:1249-54. https://doi.org/10.1200/JCO.1984.2.11.1249
  6. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42. https://doi.org/10.1046/j.1365-2168.2000.01360.x
  7. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14-8. https://doi.org/10.1007/s10120-005-0351-6
  8. Shchepotin I, Evans SR, Shabahang M, et al. Radical treatment of locally recurrent gastric cancer. Am Surg 1995;61: 371-6.
  9. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000;87:353-7. https://doi.org/10.1046/j.1365-2168.2000.01358.x
  10. Marrelli D, Roviello F, de Manzoni G, et al. Different patterns of recurrence in gastric cancer depending on Lauren's histological type: longitudinal study. World J Surg 2002;26: 1160-5. https://doi.org/10.1007/s00268-002-6344-2
  11. Lim DH, Kim DY, Kang MK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. Br J Cancer 2004;91:11-7. https://doi.org/10.1038/sj.bjc.6601896
  12. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240: 808-16. https://doi.org/10.1097/01.sla.0000143245.28656.15
  13. Lehnert T, Rudek B, Buhl K, Golling M. Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer. Eur J Surg Oncol 2002;28:455-61. https://doi.org/10.1053/ejso.2002.1260
  14. Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003;6:142-5. https://doi.org/10.1007/s10120-003-0240-9
  15. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001;181:16-9. https://doi.org/10.1016/S0002-9610(00)00549-3
  16. Hosokawa O, Kaizaki Y, Watanabe K, et al. Endoscopic surveillance for gastric remnant cancer after early cancer surgery. Endoscopy 2002;34:469-73. https://doi.org/10.1055/s-2002-32007
  17. Song KY, Park SM, Kim SN, Park CH. The role of surgery in the treatment of recurrent gastric cancer. Am J Surg 2008;196:19-22. https://doi.org/10.1016/j.amjsurg.2007.05.056
  18. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  19. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90.
  20. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215-21. https://doi.org/10.1016/S1470-2045(08)70035-4

Cited by

  1. Systématiser l’accompagnement à l’arrêt du tabac dans la prise en charge du patient atteint de cancer vol.18, pp.5, 2014, https://doi.org/10.1007/s10269-016-2618-4
  2. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review vol.45, pp.4, 2014, https://doi.org/10.1007/s00261-020-02447-0
  3. Successful curative surgery for postoperative oesophageal recurrence of oesophagogastric junction cancer vol.13, pp.7, 2014, https://doi.org/10.1136/bcr-2020-234829